Charcot Neuro-Osteoarthropathy With Superimposed Osteomyelitis in a Nondiabetic Patient, as a Consequence of Cancer Chemotherapy: A MR-Monitored Case Report

• Published in: International journal of lower extremity wounds p. 15347346241254999
• Main Authors: Giangreco, Francesco, Iacopi, Elisabetta, Maltinti, Marco, Aringhieri, Giacomo, Goretti, Chiara, Pieruzzi, Letizia, Piaggesi, Alberto
• Format: Journal Article
• Language: English
• Published: United States 21.05.2024
• Subjects: magnetic resonance; Charcot neuro-osteoarthropathy; cancer; chemotherapy
• ISSN: 1552-6941
• DOI: 10.1177/15347346241254999

Charcot neuro-osteoarthropathy (CNO) is a manifestation of peripheral neuropathy as a chronic complication of diabetes mellitus but, less frequently, can be associated to other conditions such as alcoholism or neurotoxic therapies. An increasingly emerging cause of CNO is the use of oncological drugs which can cause neuropathic damage. The use of these therapies dramatically increased in recent years. CNO leads to a progressive degeneration of the foot's joints and to bone destruction and resorption which ends in deformities. These alterations in the foot's anatomy determine a high risk of ulceration, infection, and osteomyelitis. The superimposition of osteomyelitis on CNO increases the risk of major amputation, already high in patients suffering either from only CNO or osteomyelitis alone. We report the case of a 61-year old nondiabetic woman affected by CNO as a consequence of antiblastic therapy for breast cancer and the subsequent overlap of osteomyelitis, confirmed by magnetic resonance imaging. This case underlines how it is necessary to consider CNO as a possible complication of antiblastic therapy in the view of the severe consequences of missing its diagnosis.